“Kids shouldn't have to struggle in silence,” the boy's mother said ...

Eosinophilic esophagitis, or EoE, a chronic inflammatory disease that can make swallowing and eating painful, is becoming increasingly recognized in children. NEW YORK, May 22, 2026 /PRNewswire/ -- ...

Eupraxia Pharmaceuticals ( (TSE:EPRX)) has shared an update. Eupraxia Pharmaceuticals on May 6, 2026 reported the first EoE Histology Scoring System (EoEHSS) sub-score data from the ongoing Phase ...

Robust response in highest dose cohort after 36 weeks following a single treatment of EP-104GI Completion of a $63.2 million public offering to enable clinical trials of EP-104GI in additional ...

Please provide your email address to receive an email when new articles are posted on . Dupilumab improved esophageal distensibility and diameter at 24 weeks in EoE, with endoscopic/histologic gains.

Today, 11-year-old Logan Fitzpatrick of Malverne, New York, spends his time playing baseball, practicing tae kwon do, ...

The Greek Ophthalmological Society has issued a strong warning to the public, rejecting claims that eye drops can correct ...

APEX Part B met all primary and secondary endpoints with high statistical significance; mid-dose zumilokibart planned to advance into Phase 3 ...

Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company ...

Among parents of children/adolescents with food allergy, strict allergen avoidance practices and oral food challenge history ...

Up to $1.3 billion in flexible, non-dilutive capital, including up to $800 million of synthetic royalty and access of up to $500 million in senior corporate debt Combined with company's current total ...